In conclusion, through the characterization of a novel transplantable murine lymphoma that resembled clinical PTCL‐GATA3, we provide the first evidence for ATR inhibition as a candidate therapy for PTCL. Here, GATA3 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.